| 1 |
World Health Organization. Weekly epidemiological update on COVID-19- 21 December 2022[EB/OL]. (2022-12-21) [2022-12-24].
URL
|
| 2 |
Callaway E. Heavily mutated Omicron variant puts scientists on alert[J]. Nature, 2021, 600(7887)：21.
|
| 3 |
Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa[J]. Science, 2022, 376(6593)：eabn4947.
|
| 4 |
Nimmo A, Gardiner D, Ushiro-Lumb I, et al. The global impact of COVID-19 on solid organ transplantation: two years into a pandemic[J]. Transplantation, 2022, 106(7)：1312-1329.
|
| 5 |
国家卫生健康委办公厅，国家中医药局综合司. 关于印发新型冠状病毒感染诊疗方案(试行第十版)的通知[EB/OL]．(2023-01-06)[2023-01-07].
URL
|
| 6 |
刘又宁. 奥密克戎变异株的出现将如何影响疫情的发展[J]. 中华结核和呼吸杂志，2022, 45(2)：131-132.
|
| 7 |
陶焱炀. 奥密克戎变异株引起的新型冠状病毒肺炎流行病学分析[J]. 国际流行病学传染病学杂志，2022, 49(5)：314-319.
|
| 8 |
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1[J]. N Engl J Med, 2020, 382(16)：1564-1567.
|
| 9 |
Hirose R, Itoh Y, Ikegaya H, et al. Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1 and BA.2 have higher stability[J]. Clin Microbiol Infect, 2022, 28(11)：1486-1491.
|
| 10 |
刘莹. 广州市输入性2019新型冠状病毒奥密克戎与德尔塔变异株感染者的临床特征分析[J]. 中华传染病杂志，2022, 40(10)：584-590.
|
| 11 |
中华医学会呼吸病学分会危重症学组，中国医师协会呼吸医师分会危重症医学专家组. 奥密克戎变异株所致重症新型冠状病毒感染临床救治专家推荐意见[J]. 中华结核和呼吸杂志，2023, 46(2)．
|
| 12 |
ZhengH, CaoY, ChenX, et al. Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study[J]. Cell Res, 2022, 32(8)：781-784.
|
| 13 |
Chen X, Yan X, Sun K, et al. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022[J]. Emerg Microbes Infect, 2022, 11(1)：2800-2807.
|
| 14 |
尚粉青，陈月娥，杨翰，等. 新型冠状病毒奥密克戎变异株BA.2和BA.5亚型感染者的临床特征分析[J]. 中华结核和呼吸杂志，2022, 45(12)：1199-1203.
|
| 15 |
吕莹，袁伟，施冬玲，等. 2019新型冠状病毒奥密克戎变异株感染者的临床特征分析[J]. 中华传染病杂志，2022, 40(5)：257-263.
|
| 16 |
Meo SA, Meo AS, Al-Jassir FF, et al. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics[J]. Eur Rev Med Pharmacol Sci, 2021, 25(24)：8012-8018.
|
| 17 |
马文洁，曾玫. 儿童2019新型冠状病毒感染的研究现况[J]. 中华传染病杂志，2022, 40(9)：264-268.
|
| 18 |
Wang L, Berger NA, Kaelber DC, et al. Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US[J]. JAMA Pediatrics, 2022, 176(8)：811-813.
|
| 19 |
Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature[J]. Transplant Rev (Orlando), 2021, 35(1)：100588.
|
| 20 |
Anjan S, Khatri A, Viotti JB, et al. Is the Omicron variant truly less virulent in solid organ transplant recipients？[J]. Transpl Infect Dis, 2022, 24(6)：e13923.
|
| 21 |
Ma E, Ai J, Zhang Y, et al. Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort[J]. Emerg Microbes Infect, 2022, 11(1)：2636-2644.
|
| 22 |
Zheng Z, Lu Y, Wang M, et al. Low COVID-19 vaccine coverage and guardian acceptance among pediatric transplant recipients[J]. J Med Virol, 2023, 95(1)：e28377.
|
| 23 |
许华，王晶晶，高红梅，等. 接种不同疫苗伴基础疾病新冠病毒奥密克戎变异株感染患者的临床特征分析[J]. 中华危重病急救医学，2022, 34(6): 571-575.
|
| 24 |
中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中华临床感染病杂志，2022, 15(2)：81-89.
|
| 25 |
袁伟. 新型冠状病毒奥密克戎突变株相关肝功能损害分析[J]. 中华肝脏病杂志，2022, 30(5)：513-519.
|
| 26 |
Ammirati E, Lupi L, Palazzini M, et al. Prevalence, characteristics, and outcomes of COVID-19-associated acute myocarditis[J]. Circulation, 2022, 145(15)：1123-1139.
|
| 27 |
郭晓光，罗晓洁，吴本娟，等. 317例奥密克戎变异株急性感染患者自身免疫指标的回顾性观察分析[J]. 中华危重病急救医学，2022, 34(6)：581-585.
|
| 28 |
首都儿科研究所. 首都儿科研究所附属儿童医院儿童新冠感染诊疗参考方案(2022.12)[EB/OL]. (2022-12-30)[2023-01-17].
URL
|
| 29 |
郑宜翔，李春辉，黄燕. 实体器官移植受者新型冠状病毒疫苗接种临床研究进展[J]. 中国感染控制杂志，2022, 21(2)：199-203.
|
| 30 |
刘飞，冯春月，傅海东，等. 器官移植受者新型冠状病毒肺炎疫苗接种研究进展[J]. 中华器官移植杂志，2021, 42(12)：765-768.
|
| 31 |
王玥媛，周杨林，阳柳，等. 实体器官移植受者的新型冠状病毒肺炎疫苗接种[J]. 药物不良反应杂志，2021, 23(7)：348-351.
|
| 32 |
Rivera JCHH, Mendoza MS, Covarrubias LG, et al. Mortality due to COVID-19 in renal transplant recipients, related to variants of SARS-CoV-2 and vaccination in Mexico[J]. Transplant Proc, 2022, 54(6)：1434-1438.
|
| 33 |
Gandolfini I, Crespo M, Hellemans R, et al. Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group[J]. Nephrol Dial Transplant, 2022, 37(10)：1824-1829.
|
| 34 |
Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, et al. COVID-19 in transplant recipients: the Spanish experience[J]. Am J Transplant, 2021, 21(5)：1825-1837.
|
| 35 |
Overvad M, Koch A, Jespersen B, et al. Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-a Danish nationwide cohort study[J]. Am J Transplant, 2022, 22(11)：2627-2636.
|
| 36 |
Solera JT, Árbol BG, Alshahrani A, et al. Impact of vaccination and early monoclonal antibody therapy on COVID-19 outcomes in organ transplant recipients during the Omicron wave[J]. Clin Infect Dis, 2022, 75(12)：2193-2200.
|
| 37 |
Odriozola A, San Segundo D, Cuadrado A, et al. SARS-CoV-2 and liver transplant: How has it behaved in this sixth wave？[J]. Transplantation, 2022, 106(7)：1445-1449.
|
| 38 |
中华人民共和国国家卫生健康委员会. 新冠病毒疫苗接种技术指南(第一版)[J]. 中华临床感染病杂志，2021, 14(2)：89-90.
|
| 39 |
Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus[J]. Am J Transplant, 2021, 21(8)：2719-2726.
|
| 40 |
Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series[J]. Ann Intern Med, 2021, 174(9)：1330-1332.
|
| 41 |
Ou MT, Boyarsky BJ, Motter JD, et al. Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients[J]. Transplantation, 2021, 105(10)：2170-2174.
|
| 42 |
Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials[J]. Lancet Infect Dis, 2022, 22(4)：483-495.
|
| 43 |
Schrezenmeier E, Rincon-Arevalo H, Stefanski AL, et al. B and T cell responses after a third dose of SARS-CoV-2 vaccine in kidney transplant recipients[J]. J Am Soc Nephrol, 2021, 32(12)：3027-3033.
|
| 44 |
Westhoff TH, Seibert FS, Anft M, et al. A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse[J]. Kidney Int, 2021, 100(5)：1135-1136.
|
| 45 |
World Health Organization. Interim recommendations for heterologous COVID-19 vaccine schedules[EB/OL]. (2021-12-16)[2022-12-14].
URL
|
| 46 |
Wang XY, Mahmood SF, Jin F, et al. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase Ⅲ trial[J]. Emerg Microbes Infect, 2022, 11(1)：1910-1919.
|
| 47 |
Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial[J]. Nat Med, 2022, 28(2)：401-409.
|
| 48 |
Wang Z, Zhao Z, Cui T, et al. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants[J]. Emerg Microbes Infect, 2022, 11(1): 829-840.
|
| 49 |
中华人民共和国国家卫生健康委员会. 应对新型冠状病毒肺炎疫情心理调适指南[EB/OL]．(2020-02-07) [2023-01-14].
URL
|
| 50 |
万娟，余静雅，杨平，等. 新型冠状病毒肺炎疫情下肝移植受者心理及睡眠状况调查研究[J]. 中国普外基础与临床杂志，2021, 28(12)：1619-1624.
|
| 51 |
Kadowaki M, Saito M, Amada N, et al. Medication compliance in renal transplant patients during the Great East Japan Earthquake[J]. Transplant Proc, 2014, 46(2)：610-612.
|
| 52 |
王志勇，冯全胜，于洪志，等. 清醒俯卧位治疗用于奥密克戎变异株所致普通型新冠肺炎的临床研究[J]. 中华危重病急救医学，2022, 34(6)：576-580.
|
| 53 |
Mehta A, Bansal M, Vallabhajosyula S. In COVID-19 acute hypoxemic respiratory failure, awake prone positioning vs. the supine position reduces intubations[J]. Ann Intern Med, 2022, 175(7): JC81.
|
| 54 |
Fishbane S, Hirsch JS, Nair V. Special considerations for Paxlovid treatment among transplant recipients with SARS-CoV-2 infection[J]. Am J Kidney Dis, 2022, 79(4)：480-482.
|
| 55 |
Shah A, Nasrullah A, Butt MA, et al. Paxlovid with caution: novel case of Paxlovid-induced tacrolimus toxicity in a cardiac transplant patient[J]. Eur J Case Rep Intern Med, 2022, 9(9)：003528.
|
| 56 |
Lange NW, Salerno DM, Jennings DL, et al. Nirmatrelvir/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants[J]. Am J Transplant, 2022, 22(7)：1925-1926.
|
| 57 |
Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications[J]. Clin Pharmacol Ther, 2022, 112(6)：1191-1200.
|
| 58 |
Villamarín M, Márquez-Algaba E, Esperalba J, et al. Preliminary clinical experience of molnupiravir to prevent progression of COVID-19 in kidney transplant recipients[J]. Transplantation, 2022, 106(11)：2200-2204.
|
| 59 |
Radcliffe C, Palacios CF, Azar MM, et al. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge[J]. Am J Transplant, 2022, 22(10)：2458-2463.
|
| 60 |
Poznański P, Augustyniak-Bartosik H, Magiera-Z·ak A, et al. Molnupiravir when used alone seems to be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients[J]. Viruses, 2022, 14(10)：2224.
|
| 61 |
Elec F, Magnusson J, Elec A, et al. COVID-19 and kidney transplantation: the impact of remdesivir on renal function and outcome - a retrospective cohort study[J]. Int J Infect Dis, 2022, 118: 247-253.
|
| 62 |
Bertrand D, Laurent C, Lemée V, et al. Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients[J]. Kidney Int, 2022, 102(2)：440-442.
|
| 63 |
Del Bello A, Marion O, Izopet J, et al. Can the COVID-19 pandemic improve the management of solid organ transplant recipients？[J]. Viruses, 2022, 14(9): 1860.
|
| 64 |
季茹，霍枫，陈建雄，等. 重大疫情期器官捐献与移植国际经验对新型冠状病毒肺炎疫情期相关防控的启示[J/CD]. 中华移植杂志：电子版，2020, 14(1)：6-11.
|